PA
NYMX

PSI Advisors’s Nymox Pharmaceutical Corp NYMX Stock Holding History

PSI Advisors’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,200
Closed -$388 – 831
2022
Q4 		$388 Buy
1,200
+200
+20% +$72 ﹤0.01% 716
2022
Q3 		$0 Hold
1,000
– – ﹤0.01% 860
2022
Q2 		$0 Buy
+1,000
New +$920 ﹤0.01% 874
2022
Q1 		– Sell
-8,000
Closed -$10K – 819
2021
Q4 		$10K Buy
8,000
+5,000
+167% +$7.98K ﹤0.01% 506
2021
Q3 		$6K Buy
+3,000
New +$5.32K ﹤0.01% 563

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
CF
Corrigan Financial Middletown, Rhode Island $485M AUM 4.29% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PSI Advisors's NYMX Position: Q1 2023 in Review

PSI Advisors sold out of Nymox Pharmaceutical Corp (NYMX) in Q1 2023, closing a stake of 1,200 shares — an estimated $388 sold.

PSI Advisors first reported a position in NYMX in Q3 2021 and held it in 5 quarters. The position peaked at $10K in Q4 2021. 35 funds tracked by Wall St. Rank hold NYMX as of Q1 2023.

  • PSI Advisors reported no remaining Nymox Pharmaceutical Corp position as of Q1 2023 after selling out during the quarter.
  • PSI Advisors sold 1,200 Nymox Pharmaceutical Corp shares in Q1 2023, an estimated $388.
  • PSI Advisors first reported a position in Nymox Pharmaceutical Corp in Q3 2021 and held it in 5 quarters.
  • PSI Advisors's Nymox Pharmaceutical Corp position peaked at $10K in Q4 2021.
  • 35 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q1 2023.

Based on PSI Advisors's 13F filing for Q1 2023, filed 25 Apr 2023.